ArticleCureus2022
An Unusual Side Effect of the COVID-19 Vaccine: A Possible Trigger of Polymyalgia Rheumatica.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- The Association of Polymyalgia Rheumatica and Giant Cell Arteritis With COVID-19 Vaccination: A Systematic Review.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Review
- Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.Human vaccines & immunotherapeutics · 2024Article
- Polymyalgia rheumatica and polymyalgia-like syndromes as adverse events following immunisation with COVID-19 vaccines: a 15 months update.Reumatologia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyalgia rheumatica (PMR) is characterized by myalgia and severe stiffness with decreased range of motion in the shoulder and pelvic girdles. The efficacy of the BNT 162b2 Pfizer vaccine has been proven and has been well-tolerated by patients; however, some instances of PMR have been reported after the COVID-19 vaccine. We are writing a case of a new-onset PMR in a 72-year-old woman with typical findings after receiving a booster dose of the BNT 162b2 Pfizer vaccine. This case report highlights that PMR should be in the differential diagnosis of myalgias caused by the vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.